SCYNEXIS, Inc. (SCYX)

Novel Anti-Infective Treatments

We are pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead asset, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. On June 1, 2021, SCYNEXIS received regulatory approval for its first product from the U.S. Food and Drug Administration.

Learn More About Our Product
Ibrexafungerp: A Versatile Anti-Infective

Latest News

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

Read More

SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections

Read More

SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update

Read More

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update

Read More

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

Read More

SCYNEXIS Announces Submission of Supplemental New Drug Application of ibrexafungerp to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Read More

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

Read More

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

Read More

View All News

Committed to Helping Patients Overcome and Prevent Difficult-to-Treat Infections

Our team strives to save and improve patients' lives by advancing a novel broad-spectrum antifungal therapy to address difficult-to-treat and often life-threatening infections, and to transforming the anti-infective treatment paradigms for patients worldwide.

More About Us

Our Innovative Antifungal Platform

Our lead asset, ibrexafungerp (formerly known as SCY-078), is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, known as triterpenoids.

Our Science Our Pipeline

Success Backed by Strong Leadership

The innovation that drives our science and pipeline is a direct reflection of our leadership's commitment to bringing ibrexafungerp to patients in need, and ability to advance the product across multiple indications from discovery through to the commercial stage. This leadership has a proven track record and deep antifungal expertise needed to advance ibrexafungerp to commercialization.

Leadership Board of Directors

Market/Symbol

Nasdaq: SCYX

Price

Change

52-Week Range

Daily Volume

Day Range

View Detailed Stock Info View Investor Relations View Investor Presentation